# Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

> **NCT07392541** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Advanced Biliary Tract Carcinoma

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Gemcitabine + Cisplatin
- **DRUG:** Simvastatin 20mg

## Key facts

- **NCT ID:** NCT07392541
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392541, "Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07392541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*